All articles by Andy Extance – Page 11
-
BusinessGSK stops over 30 research programmes to prioritise innovation
New boss Emma Walmsley outlines sweeping changes in order to focus on high-return drug projects
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
ResearchSaturn ring-like ‘streaming’ takes liquids into a new world
Equatorial rings that break up into uniform microdroplets could be an alternative to microfluidic emulsification techniques
-
CareersWould you rent your lab equipment?
Virtual sharing and equopment loans are making access to vital research tools easier
-
ResearchEnergy storage prices forecast to tumble
First broad ‘evidence-based’ comparison shows similar capital cost evolution among technologies including lithium-ion and flow batteries
-
ResearchChemists unravel why humans aren’t constantly bursting into flames
Strong π-bonding holds the secret to taming dioxygen diradicals
-
ResearchLilly pushes continuous drug production limits
Integrated flow synthesis and purification process for prexasertib meets high industry standards
-
ResearchScientists get charged up over titanium dioxide
Groups debate usefulness of conventional +4 titanium oxidation state compared to +2.5 charge state
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
ResearchStick-up experiment lets scientists 'see' hydrogen atoms
Upright structures offer hard-to-get direct AFM measurements
-
BusinessMerck KGaA to buy Chematica
Retrosynthesis tool will gain computational muscle and integrate with Sigma–Aldrich catalogue
-
BusinessBrexit raises regulatory worries
Risk of doubling legal burden for industry undermines referendum’s ‘red-tape cutting’ claims
-
FeatureCovalent inhibitor drugs
Exceptions to a long-held rule against chemically bonding to biological targets are powering new cancer medicines, finds Andy Extance
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
ResearchCatalyst fuels hydrogen car vision
Platinum–molybdenum carbide expedites hydrogen formation from water and methanol
-
CareersForging a future for glassblowing
Creating scientific instruments is a rare but highly desirable skill
-
ResearchUltrafast lasers promise to make lead ‘look like’ gold
Theoretical study suggests atomic mimicry could reshape spectroscopy, information processing – and even chemical reactivity
-
ResearchDo hydrogen bonds have covalent character?
Scientists wrangle over disagreement between charge transfer measurements
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity